Gastrointestinal manifestations of progressive systemic sclerosis

American Journal of Gastroenterology

Volumn 92, Issue 5, 1997, Pages 763-771

  Lock, Guntram ^a   Holstege, Axel ^a,b   Lang, Bernhard ^a,b   Schölmerich, Jürgen ^a,b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Department of Medicine ^*

Author keywords

[No Author keywords available]

Indexed keywords

OCTREOTIDE; PROKINETIC AGENT; PROTON PUMP INHIBITOR;

EARLY DIAGNOSIS; ESOPHAGUS MOTILITY; FECES INCONTINENCE; GASTROINTESTINAL SYMPTOM; HUMAN; LOWER ESOPHAGUS SPHINCTER; MANOMETRY; MUSCLE ATROPHY; PATHOPHYSIOLOGY; PNEUMATOSIS INTESTINALIS; PRIORITY JOURNAL; PSEUDOOBSTRUCTION; RECTUM PROLAPSE; REFLUX ESOPHAGITIS; REVIEW; SKIN FIBROSIS; SYSTEMIC SCLEROSIS;

DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISEASES; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 0030982192     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (103)

1. LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5 (editorial).
2. Poirier TJ, Rankin GB. Gastrointestinal manifestations of progressive systemic scleroderma based on a review of 364 cases. Am J Gastroenterol 1972;58:30-44.
3. Orringer MB, Dabich L, Zarafonetis CJD, et al. Gastro-esophageal reflux in esophageal scleroderma: Diagnosis and implications. Ann Thorac Surg 1976;22:120-30.
4. Zaninotto G, Peserico A, Costantini M, et al. Oesophageal motility and lower oesophageal sphincter competence in progressive systemic sclerosis and localized scleroderma. Scand J Gastroenterol 1989;24: 95-102.
5. Bluestone R, MacMahon M, Dawson JM. Systemic sclerosis and small bowel involvement. Gut 1969;10:185-93.
6. D'Angelo WA, Fries FJ, Masi AT, et al. Pathologic observations in systemic sclerosis (scleroderma). Am J Med 1969;46:428-40.
7. Cohen S, Laufer I, Snape WJ, et al. The gastrointestinal manifestations of scleroderma: Pathogenesis and management. Gastroenterology 1980;79:155-66.
8. Shoji I, Takagi T, Kasukawa R. Anti-centromere antibody and CREST syndrome in patients with primary biliary cirrhosis. Intern Med 1992;31:1348-55.
9. Hendel L, Worning H. Exocrine pancreatic function in patients with progressive systemic sclerosis. Scand J Gastroenterol 1989;24: 461-6.
10. Furst DE, Clements PJ, Saab M, et al. Clinical and serological comparison of 17 chronic progressive systemic sclerosis and 17 CREST syndrome patients matched for sex, age and disease duration. Ann Rheum Dis 1984;43:794-801.
11. Treacy WL, Baggenstoss AH, Slocumb CH, et al. Scleroderma of the esophagus. A correlation of histologic and physiologic findings. Ann Intern Med 1963;59:351-6.
12. Stevens MB, Hookman P, Siegel CI, et al. Aperistalsis of the esophagus in patients with connective tissue disorders and Raynaud's phenomenon. N Engl J Med 1964;270:1218-22.
13. Belch JJF, Land D, Park RHR, et al. Decreased esophageal blood flow in patients with Raynaud's phenomenon. Br J Rheumatol 1988; 27:426-30.
14. DiMarino AJ, Carlson G, Myers A, et al. Duodenal myoelectric activity in scleroderma. N Engl J Med 1973;289:1220-3.
15. Cohen S, Fisher R, Lipshutz W, et al. The pathogenesis of esophageal dysfunction in scleroderma and Raynaud's disease. J Clin Invest 1972;51:2663-8.
16. Greydanus MP, Camilleri M. Abnormal postcibal antral and small bowel motility due to neuropathy or myopathy in systemic sclerosis. Gastroenterology 1989;96:110-5.
17. Battle WM, Snape WJ, Wright S, et al. Abnormal colonic motility in progressive systemic sclerosis. Ann Intern Med 1981;94:749-52.
18. Schuffler MD, Beegle RG. Progressive systemic sclerosis of the gastrointestinal tract and hereditary hollow visceral myopathy: Two distinguishable disorders of intestinal smooth muscle. Gastroenterology 1979;77:664-71.
19. Howe S, Eaker EY, Sallustio JE, et al. Antimyenteric neuronal antibodies in scleroderma. J Clin Invest 1994;94:761-70.
20. Hendel L, Ammitzboll T, Dirksen K, et al. Collagen in the esophageal mucosa of patients with progressive systemic sclerosis. Acta Derm Venereol Stockh 1984;64:480-4.
21. Murphy JR, McInally P, Peller P, et al. Prolonged clearance is the primary abnormal reflux parameter in patients with progressive systemic sclerosis and esophagitis. Dig Dis Sci 1992;37:833-41.
22. Dantas RO, Meneghelli UG, Oliveira RB, et al. Esophageal dysfunction does not always worsen in systemic sclerosis. J Clin Gastroenterol 1993;17:281-5.
23. Weihrauch TR, Korting GW, Ewe K, et al. Esophageal dysfunction and its pathogenesis in progressive systemic sclerosis. Klin Wochenschr 1978;56:963-8.
24. Lock G, Zeuner M, Lang B, et al. Esophageal manometry in progressive systemic sclerosis: Screening procedure or confined to symptomatic patients? Gut 1995;37(suppl 2):A107.
25. Zamost BJ, Hirschberg J, Ippoliti AF, et al. Esophagitis in scleroderma. Gastroenterology 1987;92:421-8.
26. Kraus A, Alarcon Segovia D. Air esophagogram and intestinal pseudoocclusion in a patient with scleroderma. J Rheumatol 1991; 18:897-9.
27. Weihrauch TR, Korting GW. Manometric assessment of oesophageal involvement in progressive systemic sclerosis, morphea and Raynaud's disease. Br J Dermatol 1982;107:325-32.
28. Clements PJ, Kadell B, Ippoliti A, et al. Esophageal motility in progressive systemic sclerosis: Comparison of cineradiographic and manometric evaluation. Dig Dis Sci 1979;24:639-44.
29. Klein HA, Wald A, Graham TO, et al. Comparative studies of esophageal function in systemic sclerosis. Gastroenterology 1992; 102:1551-6.
30. Blom-Bulow W, Sundstrom G, Jonson B, et al. Early changes in oesophageal function in progressive systemic sclerosis: A comparison of manometry and radiology. Clin Physiol 1984;4:147-58.
31. Bhalla M, Silver RM, Shepard JA, et al. Chest CT in patients with scleroderma: Prevalence of asymptomatic esophageal dilatation and mediastinal lymphadenopathy. AJR 1993;161:269-72.
32. Akesson A, Gustafson T, Wolheim F, et al. Esophageal dysfunction and radionuclide transit in progressive systemic sclerosis. Scand J Rheumatol 1987;16:291-9.
33. Drane WE, Karvelis K, Johnson DA, et al. Progressive systemic sclerosis:radionuclide esophageal scintigraphy and manometry. Radiology 1986;160:73-6.
34. Carette S, Lacourciere Y, Lavoie S, et al. Radionuclide esophageal transit in progressive systemic sclerosis. J Rheumatol 1985;12:478-81.
35. Davidson A, Russell C, Littlejohn GO. Assessment of esophageal abnormalities in progressive systemic sclerosis using radionuclide transit. J Rheumatol 1985;12:472-7.
36. Geatti O, Shapiro B, Fig LM, et al. Radiolabelled semisolid test meal clearance in the evaluation of esophageal involvement in scleroderma and Sjoegren's syndrome. Am J Physiol Imaging 1991:65-73.
37. Adamek RJ, Wegener M, Wienbeck M, et al. Long-term manometry of tubular esophagus in progressive systemic sclerosis. Clin Investig 1994;72:343-9.
38. Adamek RJ, Wegener M, Cooremann MP. Diagnostik ösophagealer Funktionsstörungen bei progressiver systemischer Sklerodermie. Dtsch Med Wochenschr 1993;118:1327-30.
39. Shoenut JP, Wieler JA, Micflikier AB. The extent and pattern of gastro-oesophageal reflux in patients with scleroderma oesophagus: The effect of low-dose omeprazole. Aliment Pharmacol Ther 1993; 7:509-13.
40. Girsson AJ, Akesson A, Gustafson T, et al. Cineradiography identifies esophageal candidiasis in progressive systemic sclerosis. Clin Exp Rheumatol 1989;7:43-6.
41. Akesson A, Akesson B, Gustafson T, et al. Gastrointestinal function in patients with progressive systemic sclerosis. Clin Rheumatol 1985; 4:441-8.
42. Miller LS, Liu JB, Klenn PJ, et al. Endoluminal ultrasonography of the distal esophagus in systemic sclerosis. Gastroenterology 1993; 105:31-39.
43. Kemp Harper JA, Jackson DC. Progressive systemic sclerosis. Br J Radiol 1964;38:825-34.
44. Atkinson M, Summerling M.D.. Esophageal changes in systemic sclerosis. Gut 1966;7:402-8.
45. Brindley GV, Texter EG. Scleroderma of the esophagus: Medical and surgical management. Tex Med 1972;68:74-80.
46. Henderson RD, Pearson FC. Surgical management of esophageal scleroderma. J Thorac Cardiovasc Surg 1973;66:686-91.
47. Feussner H, Kreis M, Weiser HF. Motilitätsstörungen des Ösophagus bei progressiver systemischer Sklerose. Hautarzt 1988;39:291-7.
48. Johnson RB, Monroe LS. Carcinoma of the esophagus developing in progressive systemic sclerosis. Gastrointest Endosc 1973;19:189-91.
49. Bielefeld P. Sclerodermie generalisee et affections malignes: Une revue de la literature. Rev Med Interne 1991;12:350-4.
50. Denis P, Ducrotte P, Pasquis P, et al. Esophageal motility and pulmonary function in progressive systemic sclerosis. Respiration 1981; 42:21-4.
51. Johnson A, Drane WE, Curran J, et al. Pulmonary disease in progressive systemic sclerosis: A complication of gastroesophageal reflux and occult aspiration? Arch Intern Med 1989;149:589-93.
52. Troshinsky MB, Kane GC, Varga J, et al. Pulmonary function and gastroesophageal reflux in systemic sclerosis. Ann Intern Med 1994; 121:6-10.
53. Kahan A, Bour B, Couturier D, et al. Nifedipine and esophageal dysfunction in progressive systemic sclerosis: A controlled manometric study. Arthritis Rheum 1985;28:490-5.
54. Jean F, Aubert A, Bloch F, et al. Effects of diltiazeme versus nifedipine on lower esophageal sphincter pressure in patients with progressive systemic sclerosis. Arthritis Rheum 1986;29:1054-5.
55. Johnson DA, Drane WE, Curran J, et al. Metoclopramide response in patients with progressive systemic sclerosis. Arch Intern Med 1987; 147:1597-601.
56. Kahan A, Chaussade S, Gaudric M, et al. The effect of cisapride on gastro-oesophageal dysfunction in systemic sclerosis: A controlled manometric trial. Br J Clin Pharmacol 1991;31:683-7.
57. Limburg AJ, Smit AJ, Kleibeuker JH. Effects of cisapride on the esophageal motor function of patients with progressive systemic sclerosis or mixed connective tissue disease. Digestion 1993;49:156-60.
58. Wehrmann T, Caspary WF. Einfluß von Cisaprid auf die Ösophagusmotilität bei Gesunden und Patienten mit progressiver systemischer Sklerodermie. Klin Wochenschr 1990;68:602-7.
59. Horowitz M, Maddern GJ, Maddox A, et al. Effects of cisapride on gastric and esophageal emptying in progressive systemic sclerosis. Gastroenterology 1987;93:311-5.
60. Kahan A, Chaussade S, Michopoulos S, et al. Erythromycin and esophageal abnormalities in systemic sclerosis. Arthritis Rheum 1991;34:S52( 115) (abstract).
61. Fiorrucci S, Distrutti E, Bassotti G, et al. Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994;29:807-13.
62. Fiorruci S, Distrutti E, Gerli R, et al. Effect of erythromycin in gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 1994;89:550-5.
63. Hendel L, Hage E, Hendel J, et al. Omeprazole in the treatment of severe gastroesophageal reflux disease in patients with systemic sclerosis. Aliment Pharmacol Ther 1992;6:565-77.
64. Postlethwaite AE, Kang AH. Pathogenesis of progressive systemic sclerosis. J Lab Clin Med 1984;103:506-10.
65. Hendel L, Stentoft P, Aggestup S. The progress of esophageal involvement in progressive systemic sclerosis during D-penicillamine treatment. Scand J Rheumatol 1989;18:149-55.
66. Müller Ladner U, Benning K, Lang B. Current therapy of progressive systemic sclerosis (scleroderma). Clin Investig 1993;71:257-63.
67. Akesson A, Wollheim FA, Thysell H, et al. Visceral improvement following combined plasmapheresis and immunosuppressive drug therapy in progressive systemic sclerosis. Scand J Rheumatol 1988; 17:313-23.
68. Gislinger H, Burghuber OC, Stacher G, et al. Efficacy of cyclosporine A in systemic sclerosis. Clin Exp Rheumatol 1991;9:303-9.
69. Zentilin P, Savarino V, Puppo F, et al. Improvement in esophageal motor abnormalities in systemic sclerosis patients treated with cyclosporine. Arthritis Rheum 1994;37:301 (letter to the editor).
70. Clements PJ, Lachenbruch PA, Sterz M, et al. Cyclosporine in systemic sclerosis: results of a forty-eight-week open safety study in ten patients. Arthritis Rheum 1993;36:75-83.
71. O'Leary JP, Hollenbeck JI, Woodward ER. Surgical treatment of esophageal stricture in patients with scleroderma. Am Surg 1975;41: 131-5.
72. Mansour KA, Malone C. Surgery for scleroderma of the esophagus: A 12-year experience. Ann Thorac Surg 1988;46:513-4.
73. Poirier NC, Taillefer R, Topart P, et al. Antireflux operations in patients with scleroderma. Ann Thorac Surg 1994;58:66-73.
74. Topart R, Deschamps C, Taillefer R, et al. Sclerodermie et reflux oesophagien, controle chirurgical. Ann Chir 1992;46:794-9.
75. Bortolotti M, Turba E, Tosti A, et al. Gastric emptying and interdigestive antroduodenal motility in patients with esophageal scleroderma. Am J Gastroenterol 1991;86:743-7.
76. Maddern GJ, Horowitz M, Jamieson GG, et al. Abnormalities of esophageal and gastric emptying in progressive systemic sclerosis. Gastroenterology 1984;87:922-6.
77. Wegener M, Adamek RJ, Wedmann B, et al. Gastrointestinal transit through esophagus, stomach, small and large intestine in patients with progressive systemic sclerosis. Dig Dis Sci 1994;39:2209-15.
78. Madsen JL, Hendel L. Gastrointestinal transit times of radiolabeled meal in progressive systemic sclerosis. Dig Dis Sci 1992;37:1404-8.
79. Wedmann B, Wegener M, Adamek RJ, et al. Gastrobiliary motility after liquid fatty meal in progressive systemic sclerosis. Dig Dis Sci 1994;39:565-70.
80. Rohrmann CA, Ricci MT, Krishnamurty S, et al. Radiologic and histologic differentiation of neuromuscular disorders of the gastrointestinal tract: Visceral myopathies, visceral neuropathies, and progressive systemic sclerosis. AJR Am J Roentgenol 1984;143:933-41.
81. Krishnamurty S, Kelly MM, Rohrmann CA, et al. Jejunal diverticulosis: A heterogeneous disorder caused by a variety of abnormalities of smooth muscle or myenteric plexus. Gastroenterology 1983;85: 538-47.
82. Medsger TA. Treatment of systemic sclerosis. Ann Rheum Dis 1991; 50:877-86.
83. Lundberg AC, Akesson A, Akesson B. Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 1993;51: 1143-8.
84. Schuffler MD, Rohrmann CA, Chaffee RG, et al. Chronic intestinal pseudoobstruction. A report of 27 cases and review of the literature. Medicine (Baltimore), 1981;60:173-96.
85. Stafford-Brady F, Kahn HJ, Ross TM, et al. Advanced scleroderma bowel: Complications and management. J Rheumatol 1988;15:869-74.
86. Lang B, Meske S, Billmann P, et al. Spontanes Pneumoperitoneum bei progressiver Systemsklerose (generalisierter Sklerodermie). Z Rheumatol 1986;45:64-7.
87. Camilleri M, Malagelada JR, Abell TL, et al. Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudoobstruction. Gastroenterology 1989;96:704-12.
88. Soudah HC, Hasler WL, Owyang C. Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. N Engl J Med 1991;325:1461-7.
89. Owyang C. Octreotide in gastrointestinal motility disorders. Gut 1994;(suppl 3):S11-S14.
90. Ng SC, Clements PJ, Berquist WE, et al. Home central venous hyperalimentation in fifteen patients with severe scleroderma bowel disease. Arthritis Rheum 1989;32:212-6.
91. Lock G, Zeuner M, Kammerl M, et al. Gallbladder motility in systemic sclerosis. Rheumatol Int 1996;16:61-5.
92. Yabe H, Noma K, Tada N, et al. A case of CREST syndrome with rapidly progressive liver failure. Intern Med 1992;31:69-73.
93. Martel W, Chang SF, Abell MR. Loss of colonic haustration in progressive systemic sclerosis. AJR Am J Roentgenol 1976;126:704-13.
94. Mapp E. Colonic manifestations of the connective tissue disorders. Am J Gastroenterol 1981;75:386-93.
95. Basilisco G, Barbera R, Vanoli M, et al. Anorectal dysfunction and delayed colonic transit in patients with progressive systemic sclerosis. Dig Dis Sci 1993;38:1525-9.
96. Whitehead WE, Taitelbaum G, Wigley FM, et al. Rectosigmoid motility and myoelectric activity in progressive systemic sclerosis. Gastroenterology 1989;96:428-32.
97. Budd DC, Nirdlinger EL, Sturtz DL, et al. Transverse colon volvulus associated with scleroderma. Am J Surg 1977;133:370-2.
98. Baron M, Srolovitz H. Colonic teleangiectasias in a patient with progressive systemic sclerosis. Arthritis Rheum 1986;29:282-5.
99. Hamel-Roy J, Devroede G, Arhan P, et al. Comparative esophageal and anorectal motility in scleroderma. Gastroenterology 1985;88:1-7.
100. Frieling T, Enck P, Bremer G, et al. Anorektale Motilität bei systemischer Sklerodermie. Z Gastroenterol 1988;26:689-93.
101. Chiou AWH, Lin JK, Wang FW. Anorectal abnormalities in progressive systemic sclerosis. Dis Colon Rectum 1989;32:417-21.
102. Leighton JA, Valdovinos MA, Pemberton JH, et al. Anorectal dysfunction and rectal prolapse in progressive systemic sclerosis. Dis Colon Rectum 1993;36:182-5.
103. Lock G, Zeuner M, Holstege A, et al. Anorectal function in progressive systemic sclerosis: Correlation with esophageal dysfunction? Gastroenterology 1995;108:A639.